Genmab A/S (GMAB) Stock Forecast & Price Target

$22.96

+0.36 (+1.59%)

(As of 10/17/2024 ET)

Genmab A/S - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 13 Analyst Ratings

Sell
2

Hold
2

Buy
9

Based on 13 Wall Street analysts who have issued ratings for Genmab A/S in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 2 have given a sell rating, 2 have given a hold rating, and 9 have given a buy rating for GMAB.

Consensus Price Target

$45.20
96.86% Upside

According to the 13 analysts' twelve-month price targets for Genmab A/S, the average price target is $45.20. The highest price target for GMAB is $50.00, while the lowest price target for GMAB is $31.00. The average price target represents a forecasted upside of 96.86% from the current price of $22.96.

Get the Latest News and Ratings for GMAB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Genmab A/S and its competitors.

GMAB Analyst Ratings Over Time

Type	Current Forecast 10/18/23 to 10/17/24	1 Month Ago 9/18/23 to 9/17/24	3 Months Ago 7/20/23 to 7/19/24	1 Year Ago 10/18/22 to 10/18/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)	6 Buy rating(s)
Hold	2 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)	7 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)
Consensus Price Target	$45.20	$45.20	$49.50	$46.00
Forecasted Upside	96.86% Upside	71.02% Upside	78.38% Upside	56.57% Upside
Consensus Rating	Moderate Buy	Hold	Hold	Hold

AI Expert Reveals New Pick (Ad)

Everyone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released my latest prediction and believe it or not, I’m advising NOT pour all your money into Nvidia right now

Click here to see why

GMAB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GMAB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Genmab A/S Stock vs. The Competition

Type	Genmab A/S	Medical Companies	S&P 500
Consensus Rating Score	2.54	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	96.86% Upside	13,648.91% Upside	6.31% Upside
News Sentiment Rating	Positive News See Recent GMAB News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/16/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00	+115.70%
10/8/2024	Redburn Atlantic 0 of 5 stars	Q. Ding Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
9/11/2024	Morgan Stanley 3 of 5 stars		Reiterated Rating	Equal Weight ➝ Equal Weight	$31.00 ➝ $31.00	+15.63%
9/9/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$53.00 ➝ $50.00	+82.55%
8/20/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Neutral
7/15/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Campbell Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Perform ➝ Outperform
Get the Latest News and Ratings for GMAB and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.
6/27/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$46.00 ➝ $47.00	+83.09%
2/23/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$46.00 ➝ $48.00	+64.89%
1/22/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Sell
12/6/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy
11/10/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
11/8/2023	DNB Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sell ➝ Buy
10/18/2023	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Underperform
10/12/2023	Nordea Equity Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy
2/23/2023	Danske Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
2/6/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform	$33.00 ➝ $36.00	-5.91%
11/17/2022	AlphaValue Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Reduce
11/15/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$43.00	-0.23%
11/14/2022	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Phipps Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 11:46 PM ET.

Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, October 7, 2024. Please send any questions or comments about these Genmab A/S pros and cons to contact@marketbeat.com.

Genmab A/S
Bull Case

Here are some ways that investors could benefit from investing in Genmab A/S:

Genmab A/S has shown resilience in the market with a stable 50-day moving average price of $27.19, indicating consistent performance in the short term.
The company has a strong market capitalization of $18.16 billion, reflecting its size and stability in the industry.
Genmab A/S has a low P/E ratio of 22.88, suggesting that the stock may be undervalued compared to its earnings potential.
Analysts predict a positive EPS of 1.21 for the current year, indicating potential growth and profitability for investors.
Genmab A/S has a diverse portfolio of antibody therapeutics for cancer and other diseases, offering potential for significant advancements in healthcare.

Genmab A/S
Bear Case

Investors should be bearish about investing in Genmab A/S for these reasons:

Genmab A/S stock has experienced a decline in its 12-month high from $38.80 to $27.46, indicating potential volatility and downside risk.
The company reported earnings per share (EPS) below analysts' estimates, which may raise concerns about its ability to meet financial expectations.
Genmab A/S has a beta of 0.99, suggesting that the stock's price movements are closely linked to the overall market, potentially leading to higher volatility.
Despite positive ratings from analysts, there are sell ratings on the stock, indicating differing opinions on its future performance.
Investors should consider the competitive landscape in the biopharmaceutical industry, which may impact Genmab A/S' market position and growth prospects.

GMAB Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Genmab A/S is $45.20, with a high forecast of $50.00 and a low forecast of $31.00.
: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last year. There are currently 2 sell ratings, 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GMAB shares.
: According to analysts, Genmab A/S's stock has a predicted upside of 96.86% based on their 12-month stock forecasts.
: Genmab A/S has been rated by research analysts at HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Redburn Atlantic, and Truist Financial in the past 90 days.
: Analysts like Genmab A/S less than other "medical" companies. The consensus rating score for Genmab A/S is 2.54 while the average consensus rating score for "medical" companies is 2.79. Learn more on how GMAB compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

The most serious warning of my career (Ad)

With the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election.

Click here now to grab your seat now.

This page (NASDAQ:GMAB) was last updated on 10/17/2024 by MarketBeat.com Staff

From Our Partners